Treatment with Opdivo and chemotherapy improved survival in patients with gastrointestinal cancers, compared with chemotherapy alone, according to a phase 3 trial.
The Food and Drug Administration (FDA) will not be meeting the Jan. 12, 2024 approval deadline for zolbetuximab to treat certain patients with gastric or gastroesophageal junction adenocarcinoma.